NO20012721L - Plasmidopprettholdelsessystem for antigenavgivelse - Google Patents

Plasmidopprettholdelsessystem for antigenavgivelse

Info

Publication number
NO20012721L
NO20012721L NO20012721A NO20012721A NO20012721L NO 20012721 L NO20012721 L NO 20012721L NO 20012721 A NO20012721 A NO 20012721A NO 20012721 A NO20012721 A NO 20012721A NO 20012721 L NO20012721 L NO 20012721L
Authority
NO
Norway
Prior art keywords
plasmid
expression
maintenance system
expression plasmids
retention system
Prior art date
Application number
NO20012721A
Other languages
English (en)
Other versions
NO20012721D0 (no
Inventor
James E Galen
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/204,117 external-priority patent/US6413768B1/en
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of NO20012721D0 publication Critical patent/NO20012721D0/no
Publication of NO20012721L publication Critical patent/NO20012721L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Foreliggende oppfinnelse angår generelt et plasmidopprettholdelsessystem for stabilisering av ekspresjonsplasmider som koder for fremmede antigener, samt fremgangsmåter for fremstilling og anvendelse av plasmidopprettholdelsessystemet. Oppfinnelsen optimaliserer opprettholdelsen av ekspresjonsplasmider ved to uavhengige nivåer ved: (1) fjerning av avhengighet av kun balanserte letale opprettholdelses-funksjoner; og (2) innlemming av minst én plasrniddelingsfiinksjon under forhindring av tilfeldig segregasjon av ekspresjonsplasmider, hvorved deres nedarving og stabilitet forøkes. Plasmidopprettholdelsessystemet kan anvendes i et plasmid som er blitt oppbygd rekombinant for ekspresjon av mange forskjellige ekspresjonsprodukter.
NO20012721A 1998-12-02 2001-06-01 Plasmidopprettholdelsessystem for antigenavgivelse NO20012721L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/204,117 US6413768B1 (en) 1998-12-02 1998-12-02 Expression plasmids
US15873899P 1999-10-12 1999-10-12
PCT/US1999/028499 WO2000032047A1 (en) 1998-12-02 1999-12-02 Plasmid maintenance system for antigen delivery

Publications (2)

Publication Number Publication Date
NO20012721D0 NO20012721D0 (no) 2001-06-01
NO20012721L true NO20012721L (no) 2001-07-31

Family

ID=26855335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012721A NO20012721L (no) 1998-12-02 2001-06-01 Plasmidopprettholdelsessystem for antigenavgivelse

Country Status (15)

Country Link
US (6) US6703233B1 (no)
EP (1) EP1135025B1 (no)
JP (1) JP2003506007A (no)
AT (1) ATE360366T1 (no)
AU (1) AU776562B2 (no)
CA (1) CA2352457A1 (no)
CZ (1) CZ20011538A3 (no)
DE (1) DE69935927T2 (no)
DK (1) DK1135025T3 (no)
ES (1) ES2286905T3 (no)
HU (1) HUP0104609A2 (no)
NO (1) NO20012721L (no)
NZ (2) NZ529507A (no)
PL (1) PL349041A1 (no)
WO (1) WO2000032047A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ529507A (en) * 1998-12-02 2005-05-27 Univ Maryland Plasmid maintenance system for antigen delivery
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
JP4982009B2 (ja) * 1999-02-22 2012-07-25 ヘルス プロテクション エージェンシー ナイセリアワクチン組成物および方法
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
CA2382067A1 (en) * 1999-09-10 2001-03-22 The Secretary Of State For Defence Recombinant microorganisms
GB0024203D0 (en) * 2000-10-03 2000-11-15 Peptide Therapeutics Ltd Stabilisation of plasmid inheritance in bacteria
EP1917975A1 (en) 2001-11-30 2008-05-07 University of Maryland, Baltimore Novel proteins in Enteroaggregative Escherichia Coli (EAEC) useful for diagnosis and therapy of EAEC infections
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
GB0327056D0 (en) * 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
EP1706490A4 (en) * 2003-12-12 2008-02-27 Conjugon Inc STRICTLY REGULATED GENE EXPRESSION SYSTEMS
ES2431327T3 (es) * 2005-10-28 2013-11-26 University Of Maryland, Baltimore Salmonella entérica serotipo Paratyphi A atenuada y usos de la misma
US8137930B2 (en) 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009011940A2 (en) * 2007-04-06 2009-01-22 University Of Maryland, Baltimore Microcin h47 plasmid selection system
EP2152883A4 (en) * 2007-05-10 2010-10-27 Univ Arizona RECOMBINANT BACTERIA COMPRISING VECTORS FOR THE EXPRESSION OF NUCLEIC ACID SEQUENCES ENCODING ANTIGENS
WO2009025888A2 (en) * 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US20100196951A1 (en) * 2007-07-12 2010-08-05 University Of Medicine And Dentistry Of New Jersey Antitoxin Destabilization Technology
WO2009046449A1 (en) * 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
JP5210675B2 (ja) * 2008-03-19 2013-06-12 株式会社東芝 不揮発性半導体記憶装置及びその製造方法
ES2473605T3 (es) 2008-06-03 2014-07-07 University Of Maryland, Baltimore ClyA no hemol�tica para la excreci�n de proteínas
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
US8889121B2 (en) 2010-01-22 2014-11-18 The Arizona Board Of Regents For An On Behalf Of Arizona State University Bacterium comprising a regulated rfaH nucleic acid
WO2011150421A2 (en) 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US9217152B2 (en) 2010-11-23 2015-12-22 Oslo Universitetssykehus Hf DinQ-sRNA type I toxin-antitoxin system for plasmid maintenance
US9198950B2 (en) 2010-11-24 2015-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Recombinant bacterium comprising a toxin/antitoxin system
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
EP2906682A4 (en) 2012-10-15 2016-06-01 Univ Maryland LIVE BACTERIAL VECTOR VACCINES EXPRESSING FOREIGN ANTIGENS INTEGRATED WITH CHROMOSOME
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
EP3105311A1 (en) 2014-02-10 2016-12-21 Univercells NV System, apparatus and method for biomolecules production
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
BR112020008652A2 (pt) 2017-11-03 2020-11-10 Takeda Vaccines, Inc. vacinas e composições imunogênicas contra zika e métodos de uso das mesmas
CN109321591B (zh) * 2018-10-22 2021-07-13 上海海洋大学 一种重组质粒及其构建方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
WO1987005932A1 (en) * 1986-03-26 1987-10-08 Genexpress Aps Biological containment
DK410783D0 (da) 1982-09-16 1983-09-09 Benzon A Salfred Fremgangsmade til stabilisering af plasmider
US4764370A (en) 1984-09-12 1988-08-16 Scripps Clinic And Research Foundation Vaccine utilizing an avirulent strain of Salmonella typhimurium
DK275685D0 (da) 1985-06-18 1985-06-18 Benzon As Alfred Stabilisering af biologiske systemer
ATE121785T1 (de) * 1987-10-07 1995-05-15 Univ Washington Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation.
US5811105A (en) 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5695983A (en) 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
US5459072A (en) 1992-02-25 1995-10-17 Regents Of The University Of Minnesota Food-grade integration vectors for industrial bacterial strains
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5922583A (en) 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
NZ529507A (en) * 1998-12-02 2005-05-27 Univ Maryland Plasmid maintenance system for antigen delivery

Also Published As

Publication number Publication date
NZ511449A (en) 2004-05-28
ATE360366T1 (de) 2007-05-15
US20060029616A1 (en) 2006-02-09
US6703233B1 (en) 2004-03-09
NO20012721D0 (no) 2001-06-01
ES2286905T3 (es) 2007-12-01
DE69935927T2 (de) 2008-01-10
US20040161420A1 (en) 2004-08-19
AU776562B2 (en) 2004-09-16
HUP0104609A2 (hu) 2002-03-28
AU2036400A (en) 2000-06-19
US20050003539A1 (en) 2005-01-06
US7138112B2 (en) 2006-11-21
WO2000032047A1 (en) 2000-06-08
US6977176B2 (en) 2005-12-20
US6969513B2 (en) 2005-11-29
EP1135025A1 (en) 2001-09-26
US7141408B2 (en) 2006-11-28
EP1135025A4 (en) 2004-11-17
US20060030048A1 (en) 2006-02-09
US7125720B2 (en) 2006-10-24
DE69935927D1 (de) 2007-06-06
EP1135025B1 (en) 2007-04-25
PL349041A1 (en) 2002-07-01
US20060030047A1 (en) 2006-02-09
NZ529507A (en) 2005-05-27
DK1135025T3 (da) 2007-08-13
JP2003506007A (ja) 2003-02-18
CZ20011538A3 (cs) 2001-11-14
CA2352457A1 (en) 2000-06-08
WO2000032047A9 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
NO20012721L (no) Plasmidopprettholdelsessystem for antigenavgivelse
DK1445322T3 (da) Pakningssystemer for humant rekombinant adenovirus til anvendelse ved genterapi
DE69633581D1 (de) Alphavirus rna replikon-systeme
NO902995D0 (no) Stabilisert fgf-sammensetning samt fremstilling derav.
PT783314E (pt) Composicoes para o tratamento de irds e de ards, que contem pelo menos um glucocorticosteroide em combinacao com um agente tensioactivo pulmonar
CA2203149A1 (fr) Ensemble de rouleau pour le transport d'articles a temperature elevee
PT84155A (en) Method of modifying plant viruses or their effects
NO951879L (no) Polymersammensetning med forbedret termisk oksiderende stabilitet og fremgangsmåte til dens fremstilling
NO952138L (no) Cefiximpreparat
NO791101L (no) Fiberprodukt, som papir, papp e.l. samt fremgangsmaate til dets fremstilling
NO982818L (no) Syntetisk fremstilt preparat for behandling og/eller profylakse av overvekt, samt anvendelse derav
SU918453A1 (ru) Способ определени величины нечувствительности системы регулировани турбины
DK1029063T3 (da) Ikke-RCR leuconostoc-plasmid, der kan overföres til mælkesyrebakterier, anvendelse som klonings- og ekspressionsredskab
ES2160005A1 (es) Tap0n de corcho perfeccionado.
廖晓昕 et al. Stability of Hopfield-type neural networks Ⅱ
JPS5436501A (en) Internal pressure maintaining system for internal pressure type exploson- proof electric machine
NO893675D0 (no) Luftlager for aksler som skal rotere med hoeye turtall, ogaksel innrettet for opplagring i slike lager.
東孝博 The Renormalized Energy-momentum Tensor in Some Robertson-Walker Universe
AU630099B2 (en) Non-reverting rna viruses
Alekseev et al. Tunable flashlamp-pumped dye lasers
Ozeki et al. EFFECTS OF SHAPE ON BALLOONING STABILITY NEAR THE SEPARATRIX IN DIII-D
Ramsey Turbo Lightning and Strike.
Macherauch et al. Failure Considerations and Practical Dimensioning Rules for Components Under Quasi-static Loading
守屋靖代 3. The Role of Alliteration in the Alliterative Revival: Sir Gawain and Piers Plowman
王基琨 ANALYSIS OF THE PERIODIC VOLTERRA PREDATOR-PREY MODEL WITH UNDERCROWDING EFFECT

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application